Bruker Corporation (Nasdaq: BRKR)...Atomic Force Microscopy Fluorescence Microscopy Surface Analysis Systems CALID Group Life Science Mass Spec Microbiology & Diagnostics Optical Spectroscopy

© Bruker Corporation

Bruker drives customer success and profitable growth by enabling scientific discoveries and delivering high-performance analytical, life science, pharmaceutical and diagnostic solutions.

Innovation with Integrity

Bruker Corporation (Nasdaq: BRKR)

Bruker Corporation Safe Harbor Statement

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements

within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Security Exchange Act of

1934, as amended, including statements regarding management’s expectations for future financial and operational

performance, expected growth and business outlook; statements regarding our business and investment focus; expected

success of our portfolio or technology investments; and payments of any future dividends. Forward-looking statements are

based on current expectations, forecasts and assumptions of our management and are subject to risks and uncertainties that

could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating

to: adverse changes in conditions in the global economy and volatility in the capital markets; the integration of businesses we

have acquired or may acquire in the future; fluctuations in foreign currency exchange rates; implementation of strategies for

improving our operating margins, profitability and cash flow; changing technologies; product development and market

acceptance of our products; the cost and pricing of our products; competition; dependence on collaborative partners, key

suppliers and contract manufacturers; capital spending and government funding policies; changes in governmental regulations;

the use and protection of intellectual property rights and other risk factors discussed from time to time in our filings with the

Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our most

recent reports filed with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December

31, 2017, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any

intent or obligation to update these forward-looking statements other than as required by law.

2 © Bruker Corporation

30%

10%

29%

31%

Bruker Overview

Differentiated Leader in Attractive, Diverse Life Science and Diagnostic Tools Markets

3

NANO Group Advanced X-Ray Atomic Force Microscopy Fluorescence Microscopy Surface Analysis Systems Semiconductor Metrology

CALID Group Life Science Mass Spec Microbiology & Diagnostics Optical Spectroscopy Security Applications

• Founded in 1960, Bruker brand stands for innovation

• Market leader in high-value scientific instruments and analytical solutions

• FY 2017 revenue: ~$1.77 billion

• R&D investment: ~9% of revenue

• >6,000 employees worldwide

• 2019-2023 dual strategy:

Project Accelerate and Operational Excellence

• Long-term oriented ownership: about 1/3 owned by Laukien family shareholders

BIOSPIN Group Magnetic Resonance: NMR, EPR, preclinical MRI and PET/MR

BEST Group Superconductors for Science & Medicine Big Science /Fusion

Life Science Research in Academia, Medical Schools and Government

Pharma & Biopharma

Microbiology & Molecular Diagnostics

Applied Markets

Industrial Research & Semiconductor Metrology

Superconductors for Science & Medicine

Bruker revenue breakdown, % of LTM revenue(1):

(1) For the twelve months ended Sept. 30, 2018


38%

29%

[VALUE]

29%

Europe

APAC

Americas Rest of World

4%

BRUKER HOLDS #1 OR #2 MARKET POSITION FOR ~70% OF OUR PRODUCT PORTFOLIO

Market Leading Positions in Scientific Instruments

NMR & EPR Spectroscopy

Preclinical Imaging: MRI, MPI, PET/MR, microCT

MALDI BioTyper for Microbiology

Atomic Force Microscopy

4

Mass Spec Imaging, MALDI-TOF & MRMS

X-Ray Diffraction Next Gen Semicon Metrology

BEST Superconductors & ‘Big Science’ Technologies

FT-IR/NIR Spectroscopy & Microscopy

Atomic Force Microscopy (AFM)

Next-Gen X-ray & AFM Semiconductor

Metrology

X-Ray Diffraction (XRD) & Crystallography


Bruker Key Objectives for 2019-2023

5 Non-GAAP operating margin and ROIC are non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures is available at the end of this presentation and on Bruker’s website at http://ir.bruker.com/investors/press-releases/earnings-releases/default.aspx

2. Transform portfolio with six high-growth, high-margin Project Accelerate initiatives

1. Accelerate revenue growth

3. Drive Operational Excellence, sustain multi-year margin expansion

4. Disciplined capital deployment and high ROIC

• Enhance organic revenue growth with Project Accelerate initiatives

• Expand operating margin 75-100 bps per year, on average, over a multi-year timeframe

• Ongoing commercial, product R&D and operational excellence initiatives

• Strategically focused M&A in support of dual strategy

• Quarterly dividend $0.04 per share and periodic share repurchases

• BRKR ROIC >20% (FY2017 and FY2016)

Proteomics & Phenomics

Biopharma & Applied

Microbiology & Diagnostics

Neuroscience & Cell Microscopy

Next-gen Nanotech & Semi Tools

After-Market


6

• Managing our core business for profitable growth

• Transforming the portfolio with six high-growth, high-margin Project Accelerate initiatives

• Driving Operational Excellence in research & development, sales & marketing and operations

Bruker Core Values: Innovation with Integrity

Bruker 2019-2023 Strategy

Project Accelerate and Operational Excellence drive customer success and sustainable profitable growth

Commercial Excellence

Product R&D Excellence

Operational Excellence


Bruker is very well-positioned in diverse and attractive life science tools & diagnostics markets

Profitable Growth

Portfolio Cost

2018 2019E 2020E 2021E 2022E 2023E

Proteomics &

Phenomics

Biopharma &

Applied

Microbiology &

Diagnostics

Neuroscience

& Cell Microscopy

Next-gen Nanotech

& Semi Tools

After-market

7

Portfolio Transformation

Reshaping our portfolio for faster growth and higher margins* Portfolio


timsTOF Pro Proteomics, 1.0 GHz NMR

Advanced NMR and mass spec solutions for biologics and small molecule drug discovery, development and QA/QC FTIR, NIR, Raman, NMR and mass spec solutions for applied markets, e.g. food analysis

MALDI Biotyper & consumables ramp, Bruker-Hain MDx assays

2P+ multiphoton, lattice light sheet microscopy, SPIM ramp

Unique X-ray metrology and automated AFM tools

Services & consumables

Mass spec based Phenomics, 1.2 GHz NMR

Blood culture ID, susceptibility testing, Liquid Arrays™

Further next-gen microscopy products

XCD ramp

Scientific software expansion

* Chart shows approximate timeline for financially relevant contributions from Project Accelerate initiatives and product cycles.

Portfolio Transformation Update Proteomics & Phenomics Initiative

Structural Biology by GHz-Class NMR

Phenomics by NMR and Mass Spec

Proteomics by Mass Spec

• GHz+ NMR provides dynamics and function of proteins

• Ideal for Intrinsically Disordered Proteins (IDP) research

PROGRESS UPDATE: At least one system expected in

revenue in 2019

1.1 GHz at field in factory

• timsTOF Pro trapped ion mobility with PASEF offers highest sensitivity, dynamic range, throughput and robustness

PROGRESS UPDATE: KOL evaluations and early ramp-up

Unique proteomics and lipidomics workflows added in 2018

Further software advances

-

• Bruker NMR is a core technology in phenomics research

PROGRESS UPDATE: Expanding into biobank analysis

and lab developed tests (LDTs)

New large-scale phenomics center at Murdoch U. to integrate Bruker NMR and mass spec

8

Portfolio


Portfolio Transformation Update timsTOFTM Pro with PASEF enables throughput and sensitivity improvements in proteomics

9

Portfolio


4D separations with timsTOF TM Pro and PASEF method

enable superior throughput and sensitivity

Examples:

• >4,000 HeLa protein groups identified in 30 min (50 samples/day)

• >1,600 HeLa protein groups identified from just 12 cells

• Large-scale collision cross sections (CCS) enhances proteomics,

may revolutionize lipidomics and metabolomics

ng

0 3.1

6.25 12.5

25 50

100

- only 3.1 ng of sample amount - corresponds to ~12 HeLa cells

• timsTOF Pro with unprecedented robustness for proteomics

• Steady progress with further developments, key opinion leader

evaluations and commercial launch in 2018

Portfolio Transformation Update Enabling integrated NMR and MS solutions for serum and urine phenomics at Murdoch University, Western Australia

10

Portfolio


“Our collaboration with Bruker for multiple NMR and mass spec platforms enables the creation of a large-scale facility and Center of Excellence at Murdoch. In addition to healthcare research, the Center will also focus on the role nutrition and the environment play in an individual’s cellular function. Such precise data will allow clinicians to better predict health problems and intervene earlier, saving time, money and lives. The potential of integrated phenomics to provide truly personalized care is remarkable.”

• Bruker system types ordered recently by Murdoch University (Perth, WA):

impact-II ‘phenomics workhorse’ UHR-QTOF for robust, high-sensitivity LC-MS/MS

FIA-MRMS for high-throughput phenomics analysis

timsTOF Pro: LC/CCS/MS/MS for metabolomics and lipidomics identification

Avance IVDr 600: 1D&2D NMR ‘gold standard’ at International Phenome Center Network (IPCN) for targeted and untargeted quantification of metabolites

Integrated NMR, FIA-MRMS and LC-QTOF platforms to enable novel phenomics research and large cohort validation studies

- Prof. Jeremy Nicholson, ProVice Chancellor of Health Sciences at Murdoch U., and Executive Director, Australian National Phenome Center

Portfolio Transformation Update Novel NMR Magnet at 1.1 GHz reaches field in factory test

11

Portfolio


First ever high-resolution 1.1 GHz NMR spectra with novel high-temperature & low-temperature superconductor hybrid magnet

Novel HTS/LTS hybrid 1.1 GHz magnet in factory test

ppm

6.06.57.07.58.08.59.09.5 ppm

20

30

40

50

60

70

Sample protein: 0.5mM Ubiquitin, 13C/15N labeled

Expt. Time: 3.5 hours with NUS

2D NMR HN(CO)CACB Watergate Experiment at 1.1 GHz

3D NMR best-TROSY-HNCACB Experiment at 1.1 GHz

Bruker Biopharma Solutions

• Differentiated NMR, Mass Spec, SPR, FTIR, Raman and X-ray solutions for pharma and biopharma applications

PROGRESS UPDATE: NMR solutions: fragment screening, biologics

higher order screening, structure activity, reaction monitoring, etc.

Mass spec portfolio: MALDI PharmaPulse uHTS, timsTOF Pro for proteomics, maXis II for mAb and antibody drug conjugates (ADC); ScimaX MRMS imaging for drug development

• NMR, Mass Spec and FTIR solutions for food quality, authenticity and safety testing

Example: NMR FoodScreenerTM quantifies ingredients in honey, wine, juice, olive oil and flavors with higher specificity and throughput

PROGRESS UPDATE: Additional NMR FoodScreener methods

New FTIR/NIR solutions for dairy markets

Portfolio Transformation Update Biopharma & Applied Markets Initiative

Bruker Applied Markets Solutions

12

Portfolio


Portfolio Transformation Update Microbiology & Diagnostics Initiative

13

MALDI Biotyper identifies bacteria, yeasts and

fungi accurately and with shorter time-to-result

• Global installed base ~3,200 system

• ‘Gold standard’ for fast and cost-effective ID

• 50% of business is after-market revenue

• Comprehensive roadmap:

− SepsiTyper™ fast ID from blood culture: launched in Europe, US FDA trials 2019E

− Select antibiotic resistance and susceptibility testing work in progress

Clinical Microbiology Expanding Consumables Portfolio • MBT Star®-Carba and MBT Star® Cepha CE-IVD

assay for antibiotic resistance on Biotyper

• ‘Bologna’ CE-IVD fast ID and resistance workflow for bloodstream infections

• High-value invasive fungal disease PCR assays

• Merlin Antibiotic Resistance & Susceptibility Testing specialty assays

• Complementary Bruker-Hain Molecular Dx portfolio for mycobacteria and viral pathogens

• On roadmap: Syndromic Panels

Portfolio


Portfolio Transformation Update Hain adds breadth and further growth drivers to Bruker’s Microbiology & Diagnostics portfolio

14

1996

FluoroType®: 2012

PCR with melting curve analysis

High-precision

real-time PCR: 2018

DNA•STRIP GenoType tests

• Established MDx test portfolio for Tb screening and resistance testing

• MDx assays for microbial and viral pathogens

• New Fluorocycler™ XT system and work-in-progress Liquid Array™ assays for cost-effective syndromic panels

• 2019E revenue: ~$40M

• 2019E non-GAAP EPS accretion: +$0.01 to +$0.02

Liquid Array™

TB panel: 2019E

Syndromic panels: 2021E and beyond


Portfolio

Portfolio Transformation Update Neuroscience & Cell Microscopy Initiative

• Simultaneous, all-optical stimulation and imaging platforms for Optogenetic Neuroscience research

• Next-gen Multiphoton, Super-Resolution and Light Sheet Cell Microscopy systems enable brain research and high-resolution live-cell research

PROGRESS UPDATE: Three important products launched in late 2018:

- First ever, tailorable next-gen lattice light sheet (lattice, Bessel, Gaussian)

- Light Sheet clearing module for Neuroscience

- Next-gen 2P+ multiphoton system

Fluorescence Microscopy

Mouse spermatocyte courtesy of Jackson Labs

15

3D Spheroid with Lattice Light Sheet HeLa Cells with Bessel beam


Portfolio

Portfolio Transformation Update Next-Gen Nanotech & Semi Tools Initiative

Next-Gen Nanotechnology & Semiconductor Metrology

• Logic and memory require next-gen nano-metrology

tools to ensure yield and quality

• Bruker next-gen atomic force microscopy (AFM) and

X-ray metrology tools are key for advanced nodes and

3D chip structures

PROGRESS UPDATE: X-Ray Critical Dimension (XCD) semi tool developed,

key customer evaluations expected in 2019


Portfolio

Bruker Services, Software and Consumables

PROGRESS UPDATE: Services, software and consumables continue to be a

key growth and operating margin driver

Hain majority acquisition (Oct. 2018) adds to consumables portfolio

MestreLab majority acquisition (Dec. 2018) a foundation for new scientific software strategy


Fast Growing After-Market Business Services, Software and Consumables Initiative Portfolio

Strategically Focused M&A in 2018 M&A supports Project Accelerate, improves operating margin mix and strengthens core

IRM2

Support Core Business Transform Portfolio (ACCELERATE)

Org

anic

Rev

enu

e G

row

th R

ate

Higher Growth

Lower Growth

18 *Hain Diagnostics and Mestrelab Research are majority interest acquisitions.


Portfolio

19

2018 2019E 2020E 2021E

BIOSPIN

Project 2020 Lean lay-out, site consolidation

and reinvestment in DE&CH

CALID

Project Green Restructuring & consolidation

of CBRNE Detection business

NANO

Penang, Malaysia New lower cost final

assembly & test center

BRUKER

Warsaw BSC EU shared services center

driving efficiencies at lower cost

Cost

2018 - 2021E

2019E-2021E

Late 2018 – 2019E


2018-2019E

Operational Excellence & Cost Optimization

• Product R&D Excellence

• Lean Manufacturing

• Operational Excellence

• Commercial Excellence

• SAP ERP, SalesForce CRM

• Risk management

Driving Operating Leverage through continuous

Operational Excellence: selected initiatives

Bruker 2015 to LTM Q3 2018 Financials

Accelerating revenue growth and healthy margin expansion drive EPS

$1.62B $1.61B

$1.77B

$1.87B

FY 2015 FY2016 FY 2017LTM Q3 2018*

Revenue

(1)Non-GAAP operating margin and non-GAAP EPS are non-GAAP measures. Reconciliations of these measures to the most directly comparable GAAP measures are available at the end of this presentation and on Bruker’s website at https://ir.bruker.com/financial-info/quarterly-results/default.aspx

20

*For the last twelve months ended September 30, 2018


13.5%

15.0%

15.9% 16.4%

FY 2015 FY2016 FY 2017 LTM Q3 2018*

Non-GAAP Operating Margin(1)

$0.89

$1.19 $1.21

$1.37

FY 2015 FY2016 FY 2017 LTM Q3 2018*

Non-GAAP EPS(1)

https://ir.bruker.com/financial-info/quarterly-results/default.aspx





21

Organic R&D investment

Capital expenditures

Strategically focused M&A

Annual dividend of

$0.16 per share

Periodic share

repurchases

FY 2015 FY 2016 FY 2017

22.9% 27.6% 27.3%

ROIC Performance(1)

Invest in growing

the business

Maintain financial

flexibility

Return capital to

shareholders

Disciplined Capital Deployment

Leading ROIC Performance


Strong, flexible balance

sheet

Conservative debt levels

(1)Return on Invested Capital (ROIC) is a non-GAAP measure. A reconciliations of this measure to the most directly comparable GAAP measures is available at the end of this presentation and on Bruker’s website at https://ir.bruker.com/financial-info/quarterly-results/default.aspx







www.bruker.com

22

Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (unaudited)

© Bruker Corporation 23

(1)The Company adopted Accounting Standards Update (ASU) 2017-07 as of January 1, 2018 under the retrospective approach. Accordingly, the 2015, 2016 and 2017 income statement accounts have been restated to reflect ASU 2017-07.

(in millions, except per share amounts)

Three

Months

Ended

December

Nine Months

Ended

September 30,

Trailing

Twelve

Months Ended

September 30,

2015 (1)

2016 (1)

2017 (1)

2017 (1)

2018 2018

Reconciliation of Non-GAAP Operating Income, Non-GAAP

Profit Before Tax, Non-GAAP Net Income, and Non-GAAP

GAAP Operating Income 160.2$ 181.8$ 219.5$ 95.3$ 156.0$ 251.3$

Non-GAAP Adjustments:

Restructuring Costs 29.3 20.8 16.2 7.7 6.7 14.4

Acquisition-Related Costs (4.7) 11.1 10.2 0.8 3.9 4.7

Purchased Intangible Amortization 20.8 21.7 29.6 7.0 21.5 28.5

Other Costs 13.9 7.1 5.4 1.6 7.0 8.6

Total Non-GAAP Adjustments: 59.3$ 60.7$ 61.4$ 17.1$ 39.1$ 56.2$

Non-GAAP Operating Income 219.5$ 242.5$ 280.9$ 112.4$ 195.1$ 307.5$

Non-GAAP Operating Margin 13.5% 15.0% 15.9% 21.2% 14.5% 16.4%

Non-GAAP Interest & Other Expense, net (21.8) (13.4) (22.3) (6.2) (11.5) (17.7)

Non-GAAP Profit Before Tax 197.7 229.1 258.6 106.2 183.6 289.8

Non-GAAP Income Tax Provision (43.4) (35.9) (64.7) (26.0) (47.0) (73.0)

Non-GAAP Tax Rate 22.0% 15.7% 25.0% 24.5% 25.6% 25.2%

Minority Interest (3.3) (0.9) (1.7) (0.4) (1.5) (1.9)

Non-GAAP Net Income Attributable to Bruker 151.0 192.3 192.2 79.8 135.1 214.9

Weighted Average Shares Outstanding (Diluted) 169.1 162.2 159.1 156.9 157.2

Non-GAAP Earnings Per Share 0.89$ 1.19$ 1.21$ 0.51$ 0.86$ 1.37$

Twelve Months Ended December 31,

Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited)



Three

Months

Ended

December

Nine Months

Ended

September 30,

Trailing

Twelve

Months Ended

September 30,

2015 (1)

2016 (1)

2017 (1)

2017 (1)

2018 2018

Reconciliation of GAAP and Non-GAAP Gross Profit

GAAP Gross Profit 711.2$ 745.3$ 816.0$ 256.2$ 627.2$ 883.4$



Acquisition-Related Costs 2.5 2.1 5.7 0.1 1.6 1.7


Other Costs - 0.1 0.8 0.1 - 0.1

Total Non-GAAP Adjustments: 42.4 31.9 36.1 9.8 19.0 28.8

Non-GAAP Gross Profit 753.6$ 777.2$ 852.1$ 266.0$ 646.2$ 912.2$

Non-GAAP Gross Margin 46.4% 48.2% 48.3% 50.1% 48.2% 48.7%

Reconciliation of GAAP and Non-GAAP Tax Rate

GAAP Tax Rate 18.0% 13.0% 59.4% 103.4% 28.7%


Tax Impact of Non-GAAP Adjustments -1.5% -1.0% -0.1% -1.6% -0.2%

Tax Authority Settlements -0.8% 0.1% 0.0% 0.0% 0.0%

Valuation Allowance Release 6.8% 3.7% 0.0% 0.0% 0.0%

U.S. Tax Reform- Toll Charge 0.0% 0.0% -27.8% -62.1% -2.6%

U.S. Tax Reform- Tax Rate Change 0.0% 0.0% -0.6% -1.3% 0.0%

U.S. Tax Reform- Change in APB 23 0.0% 0.0% -6.5% -14.4% 0.0%

Other Discrete Items -0.5% -0.1% 0.6% 0.5% -0.3%

Total Non-GAAP Adjustments: 4.0% 2.7% -34.4% -78.9% -3.1%

Non-GAAP Tax Rate 22.0% 15.7% 25.0% 24.5% 25.6%






Three

Months

Ended

December

Nine Months

Ended

September 30,

Trailing

Twelve

Months Ended

September 30,

2015 (1)

2016 (1)

2017 (1)

2017 (1)

2018 2018

Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)

GAAP Earnings Per Share (Diluted) 0.60$ 0.95$ 0.49$ (0.02)$ 0.65$ 0.63$



Acquisition-Related Costs (0.03) 0.07 0.06 0.01 0.03 0.04


Other Costs 0.08 0.04 0.04 0.01 0.04 0.05

Bargain Purchase Gain - (0.06) - - - -

Pension Settlement Charge 0.06 - - - - -

Income Tax Rate Differential (0.12) (0.08) 0.33 0.42 (0.04) 0.38

Total Non-GAAP Adjustments: 0.29 0.24 0.72 0.53 0.21 0.74

Non-GAAP Earnings Per Share (Diluted) 0.89$ 1.19$ 1.21$ 0.51$ 0.86$ 1.37$

Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net

GAAP Interest & Other Income (Expense), net (32.2)$ (4.2)$ (21.7)$ (6.7)$ (11.5)$ (18.2)$


Bargain Purchase Gain - (9.2) (0.6) 0.5 - 0.5

Pension Settlement Charge 10.2 - - - - -

Sale of Product Line 0.2 - - - - -

Non-GAAP Interest & Other Income (Expense), net (21.8)$ (13.4)$ (22.3)$ (6.2)$ (11.5)$ (17.7)$







Three

Months

Ended

December

Nine Months

Ended

September 30,

Trailing

Twelve

Months Ended

September 30,

2015 (1)

2016 (1)

2017 (1)

2017 (1)

2018 2018

Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow

GAAP Operating Cash Flow 229.2$ 130.8$ 154.4$ 103.7$ 107.4$ 211.1$


Purchases of property, plant and equipment (34.2) (37.1) (43.7) (12.4) (28.9) (41.3)

Non-GAAP Free Cash Flow 195.0$ 93.7$ 110.7$ 91.3$ 78.5$ 169.8$

Reconciliation of Non-GAAP Return on Invested Capital (ROIC)

Non-GAAP Operating Income (from above) 219.5$ 242.5$ 280.9$

Less: Non-GAAP Income Tax Provision (from above) (43.4) (35.9) (64.7)

Non-GAAP Operating Income after Tax 176.1$ 206.6$ 216.2$

Average Total Invested Capital:

Average Long-Term Debt 310.1$ 328.8$ 403.6$

Average Current portion of Long-Term Debt 0.7 10.4 10.1

Average Total Shareholders' Equity 752.3 713.0 713.3

Less: Average Cash and Cash Equivalents (293.3) (304.8) (333.7)

Average Total Invested Capital 769.8$ 747.4$ 793.3$

Return on Invested Capital (ROIC) 22.9% 27.6% 27.3%




For more information, visit Bruker’s IR website at https://ir.bruker.com/financial-info/quarterly-results/default.aspx

With respect to the Company's outlook for 2018 non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, or projections for the 2019 non-GAAP EPS impact of any acquisition, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP operating margin, tax rate and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future period operating margins, EPS and tax rate calculated and presented in accordance with GAAP.


Three

Months

Ended

December

Nine Months

Ended

September 30,

Trailing

Twelve

Months Ended

September 30,

2015 (1)

2016 (1)

2017 (1)

2017 (1)

2018 2018

Reconciliation of Impact of Adoption of ASU 2017-07 (2)

Cost of revenues (2.6) (2.8) (3.0) (1.0) (1.3) (2.3)

Selling, general and administrative (0.7) (0.7) (0.7) (0.2) (0.4) (0.6)

Research and development (1.0) (1.1) (1.1) (0.4) (0.5) (0.9)

Interest and other income (expense), net 4.3 4.6 4.8 1.6 2.2 3.8

Net Impact to Net Income and Earnings per Share: - - - - - -



(2) The restatement for ASU 2017-07 below reflects the impact to the Non-GAAP financial statements. The GAAP financial statements for the twelve months ended December 31, 2015 also reflected a reclassification of $10.2 million related to pension settlements charges.






Bruker Corporation List of Commonly Used Abbreviations in Alphabetical Order


ADC: Antibody Drug Conjugate AFM: Atomic Force Microscopy BEST: Bruker Energy and Supercon Technologies CALID: Chemical, Applied Market, Life Science, In-Vitro Diagnostics & Detection CCS: Collision Cross Section EPR: Electron Paramagnetic Resonance FIA-MRMS: Flow Injection Analysis Magnetic Resonance Mass Spectrometry FTIR: Fourier Transform Infrared Spectroscopy HOS: Higher-Order Structure HTS: High Temperature Superconductors IDP: Intrinsically Disordered Proteins KOL: Key Opinion Leader LC: Liquid Chromatography LC-MS: Liquid Chromatography Mass Spectrometry LC-QTOF: Liquid Chromatography Quadrupole Time-of-Flight MS LDT: Laboratory Developed Test LTS: Low Temperature Superconductors

mAb: Monoclonal Antibody MALDI: Matrix Assisted Laser Desorption Ionization MALDI-TOF: Matrix Assisted Laser Desorption Ionization Time-of-Flight MDx: Molecular Diagnostics MPI: Magnetic Particle Imaging MRI: Magnetic Resonance Imaging NIR: Near Infrared Spectroscopy NMR: Nuclear Magnetic Resonance PASEF: Parallel Accumulation Serial Fragmentation PET/MR: Positron Emission Tomography/ Magnetic Resonance PCR: Polymerase Chain Reaction SPIM: Selective Plane Illumination Microscopy SPR: Surface Plasmon Resonance timsTOF: Trapped Ion Mobility Separation Time-of-Flight UHR- QTOF: Ultrahigh Resolution Quadrupole Time-of-Flight uHTS: Ultra High Throughput Screening XCD: X-Ray Critical Dimension XRD: X-Ray Diffraction

Documents

Bruker Corporation (Nasdaq: BRKR)...Atomic Force Microscopy Fluorescence Microscopy Surface Analysis Systems CALID Group Life Science Mass Spec Microbiology & Diagnostics Optical Spectroscopy